Drug Approval | August 20, 2022
Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022
Therapy recently approved in Canada under the brand name KORSUVA
Therapy recently approved in Canada under the brand name KORSUVA
Syngene's collaboration with Zoetis started in 2011
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Subscribe To Our Newsletter & Stay Updated
